FibroBiologics Announces Issuance of Canadian Patent Covering Novel Fibroblast-Based Treatment for Cachexia

Rhea-AI Summary

FibroBiologics (Nasdaq: FBLG) announced issuance of Canadian Patent No. 3118732 for “Treatment of Cachexia Using Fibroblast Cells and Products Thereof.” The patent covers composition and method claims for immune-modulating fibroblasts, stem-marker-expressing cells, and multiple dosing routes to address cachexia and related inflammation.

The filing highlights claims on marker-positive fibroblasts and methods to reduce inflammation and prevent or reverse weight loss in patients with cachexia; the company cites a cancer cachexia market projection of $3.2B by 2032.

Positive

• Issued Canadian Patent No. 3118732 covering fibroblast treatments for cachexia
• Claims include both composition and method protections for immune-modulating fibroblasts
• Patent specifies fibroblasts with distinct stem cell markers (SSEA3/4, Tra-1-60/81, Oct-4, CD markers)
• Cites a $3.2B projected cancer cachexia market by 2032, indicating commercial relevance

Negative

• Patent is limited to Canada, leaving other jurisdictions unprotected until further grants
• No new clinical efficacy or human trial results were disclosed to validate therapeutic benefit
• Company remains clinical-stage, so commercialization timelines and regulatory approvals are uncertain

News Market Reaction – FBLG

-9.20% 4.5x vol

11 alerts

-9.20% News Effect

+6.5% Peak Tracked

-23.5% Trough Tracked

-$2M Valuation Impact

$22M Market Cap

4.5x Rel. Volume

On the day this news was published, FBLG declined 9.20%, reflecting a notable negative market reaction. Argus tracked a peak move of +6.5% during that session. Argus tracked a trough of -23.5% from its starting point during tracking. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $2M from the company's valuation, bringing the market cap to $22M at that time. Trading volume was very high at 4.5x the daily average, suggesting heavy selling pressure.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Patent portfolio: 270+ patents issued and pending Cachexia cancer market: $3.2B Canadian patent number: 3118732

3 metrics

Patent portfolio 270+ patents issued and pending Company-wide intellectual property

Cachexia cancer market $3.2B Projected market size by 2032

Canadian patent number 3118732 Issued by Canadian Intellectual Property Office

Market Reality Check

Price: $0.4002 Vol: Volume 1,107,993 vs 20-da...

normal vol

$0.4002 Last Close

Volume Volume 1,107,993 vs 20-day average 1,299,855 (relative volume 0.85x) shows no unusual activity. normal

Technical Price 0.2501 is trading below the 200-day MA at 0.56 and sits between the 0.2201 52-week low and 2 high.

Peers on Argus

FBLG shows a -9.81% move while peers are mixed: GDTC +23.54%, CRIS +5.49%, ICU +...

1 Up

FBLG shows a -9.81% move while peers are mixed: GDTC +23.54%, CRIS +5.49%, ICU +4.47%, NRXS +2.59%, LIXT -1.23%. Only GDTC appears in the momentum scanner, suggesting today’s action is stock-specific rather than a coordinated biotech move.

Historical Context

5 past events · Latest: Jan 20 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 20	Conference presentation	Neutral	-3.7%	Announcement of CEO presentation at DealFlow Discovery investor conference.
Jan 07	Shareholder update	Positive	+32.3%	CEO letter detailing 2025 clinical, IP, manufacturing and financing milestones.
Jan 06	Conference presentation	Neutral	+6.8%	Notification of presentation at BFC Global Healthcare Business Development Conference.
Jan 05	Preclinical results	Positive	+1.5%	Positive preclinical FSdC spheroid data in degenerative disc disease models.
Dec 31	IND filing	Positive	-7.0%	IND submission to FDA for Phase 1/2 trial of CYPS317 in psoriasis.

Pattern Detected

Recent news has often been positive, but price reactions have been inconsistent, with some clinical and corporate milestones sold off and others attracting strong buying.

Recent Company History

Over the past few months, FibroBiologics issued several scientific, clinical, corporate, and financing updates. These included positive preclinical data for an FSdC spheroid therapy on Jan 5, 2026, an IND filing for CYPS317 on Dec 31, 2025, and a shareholder letter outlining 2025 progress and financings on Jan 7, 2026. Conference participation announcements on Jan 6 and Jan 20, 2026 rounded out investor outreach. The new Canadian cachexia patent adds to this IP‑focused trajectory, reinforcing the company’s emphasis on fibroblast-based platforms.

Market Pulse Summary

The stock moved -9.2% in the session following this news. A negative reaction despite a new Canadian...

Analysis

The stock moved -9.2% in the session following this news. A negative reaction despite a new Canadian cachexia patent could fit a pattern where positive scientific or regulatory steps, such as the Dec 31, 2025 IND filing, were followed by selling pressure. With shares already trading well below the 0.56 200-day MA and near the 0.2201 52-week low, some holders may focus more on past dilution, reverse-split proposals, and Nasdaq listing risks than on longer-term IP expansion.

Key Terms

cachexia, c-reactive protein, interleukin-1, interleukin-6, +4 more

8 terms

cachexia medical

"Cachexia, a complex metabolic syndrome characterized by severe weight loss..."

Cachexia is a complex condition characterized by significant weight loss, muscle wasting, and weakness, often occurring in people with chronic illnesses such as cancer or severe infections. It reflects a state where the body is unable to maintain healthy tissue, leading to decline in overall strength and vitality. For investors, understanding cachexia is important because it can signal underlying health issues that may impact a company's performance, especially in industries related to healthcare and pharmaceuticals.

c-reactive protein medical

"...address the root cause of cachexia and associated inflammatory mediators such as C-reactive protein, Interleukin-1..."

C-reactive protein (CRP) is a blood biomarker that rises when the body has inflammation or infection, acting like a smoke detector that signals something is wrong. For investors, CRP matters because it is used in clinical tests and drug trials to show whether treatments reduce inflammation, can influence regulators’ and doctors’ decisions, and therefore affects the commercial prospects of diagnostics and therapeutic products.

interleukin-1 medical

"...inflammatory mediators such as C-reactive protein, Interleukin-1, Interleukin-6, and TNF-alpha."

A small signaling protein the immune system uses to start and amplify inflammation; think of it as an alarm bell that tells immune cells to respond to infection or injury. For investors, interleukin-1 matters because drugs that block or modify its activity are major targets for treating inflammatory diseases, so news about clinical results, approvals, or safety can sharply affect companies developing related therapies and their market value.

interleukin-6 medical

"...mediators such as C-reactive protein, Interleukin-1, Interleukin-6, and TNF-alpha."

Interleukin-6 is a small signaling protein the body releases to coordinate inflammation and immune responses, acting like a fire alarm that summons immune cells to sites of infection or tissue damage. It matters to investors because high or persistent levels are linked to disease activity and are a common drug target or clinical trial biomarker; changes in IL-6-related data can influence a therapy's approval prospects, market potential, and a company's valuation.

tnf-alpha medical

"...Interleukin-1, Interleukin-6, and TNF-alpha."

Tumor necrosis factor-alpha (TNF-alpha) is a small signaling protein the body uses to trigger and regulate inflammation, like a fire alarm that summons immune cells to a problem site. Investors watch it because elevated or controlled TNF-alpha levels are central to many inflammatory and autoimmune diseases, making it a common target for drugs and diagnostics; success or failure of therapies that block or measure TNF-alpha can greatly affect company value and market prospects.

intravenous medical

"Methods of treatment using fibroblasts to affected individuals via various routes, such as intravenous, subcutaneous..."

Intravenous means delivering a drug, fluid or substance directly into a vein so it goes straight into the bloodstream. For investors, that matters because intravenous products often act faster, require different manufacturing, regulatory steps and healthcare settings (like hospitals or clinics), and can affect pricing, adoption and revenue profiles in ways that differ from pills or topical treatments — like turning a slow-release delivery into a direct tap to the system.

subcutaneous medical

"Methods of treatment using fibroblasts to affected individuals via various routes, such as intravenous, subcutaneous, or intramuscular..."

Subcutaneous means situated or applied just beneath the skin. In finance, the term can describe processes or investments that are hidden or not immediately visible, much like something placed under the skin that isn't easily seen from the outside. Recognizing subcutaneous activities helps investors understand underlying factors that may influence markets or asset values over time.

intramuscular medical

"via various routes, such as intravenous, subcutaneous, or intramuscular, to ameliorate cachexia..."

A way of giving a medicine or vaccine by injecting it deep into a muscle, typically using a syringe and needle so the drug is absorbed into the bloodstream more steadily than a skin shot but faster than swallowing a pill. Investors care because this delivery method affects how quickly and reliably a treatment works, the type of manufacturing and packaging needed, clinical trial design and regulatory requirements, and patient or provider preferences that influence market uptake.

AI-generated analysis. Not financial advice.

HOUSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that the Canadian Intellectual Property Office has issued Canadian Patent No. 3118732, titled “Treatment of Cachexia Using Fibroblast Cells and Products Thereof.” This patent strengthens FibroBiologics’ intellectual property portfolio and underscores the Company’s commitment to advancing innovative therapies for debilitating conditions like cachexia.

Cachexia, a complex metabolic syndrome characterized by severe weight loss, muscle wasting, and inflammation, often accompanies chronic diseases such as cancer, HIV/AIDS, and chronic obstructive pulmonary disease. The cachexia market for cancer is projected to hit $3.2B by 2032. The newly issued patent covers methods and compositions for treating cachexia or related inflammation through the administration of fibroblasts, providing a novel approach to addressing this unmet medical need.

Key components of the patent include:

• The use of immune-modulating fibroblasts, which are cultured under specific conditions to enhance their ability to suppress inflammation and address the root cause of cachexia and associated inflammatory mediators such as C-reactive protein, Interleukin-1, Interleukin-6, and TNF-alpha.
• Composition of matter claims on fibroblasts that express detectable levels of specific stem cell markers, including SSEA3, SSEA4, Tra-1-60, Tra-1-81, Tra-2-54, Oct-4, CD13, CD44, CD49b, CD105, and aminopeptidase N, while not expressing detectable levels of SSEA1, enabling their potential to restore physiological, immunological, and metabolic homeostasis.
• Methods of treatment using fibroblasts to affected individuals via various routes, such as intravenous, subcutaneous, or intramuscular, to ameliorate cachexia, prevent weight loss, or increase weight in patients at risk for, or suffering from, the condition.
  
  

“We are thrilled with the issuance of this Canadian patent, which represents an important step forward in our pioneering work to leverage the regenerative and immunomodulatory properties of fibroblasts to combat cachexia, a condition that significantly impacts patient quality of life and outcomes in chronic diseases,” said Pete O’Heeron, Founder and Chief Executive Officer of FibroBiologics. “This milestone not only expands our global IP protection but also brings us closer to delivering transformative therapies that could change the standard of care for millions of patients worldwide.”

About FibroBiologics

Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.

Cautionary Statement Regarding Forward-Looking Statements

This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning the scope and strength of the Company’s intellectual property portfolio, the potential indications for FibroBiologics’ programs, the potential clinical benefits of fibroblasts and fibroblast-derived materials in cachexia, and the potential cachexia market for cancer. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, www.sec.gov. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of FibroBiologics’ R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; and (d) the ability of FibroBiologics to successfully prosecute its patent applications. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update, or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations.

General Inquiries:
info@fibrobiologics.com

Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com

Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com

FAQ

What does FibroBiologics (FBLG) patent No. 3118732 cover for cachexia treatment?

It covers methods and compositions using fibroblast cells to treat cachexia and related inflammation. According to the company, claims include immune-modulating fibroblasts, specific stem-cell marker profiles, and various administration routes such as IV, subcutaneous, and intramuscular.

How significant is the Canadian patent for FBLG investors and market opportunity?

The patent strengthens FibroBiologics' intellectual property position in Canada for fibroblast-based cachexia therapies. According to the company, this complements its 270+ patents issued/pending and points to a cited cancer cachexia market projected at $3.2B by 2032.

Does the new patent from FibroBiologics (FBLG) guarantee a new treatment is available now?

No, the patent grants IP rights but does not imply an approved therapy is available. According to the company, it protects methods and compositions while clinical development and regulatory approvals remain necessary before commercialization.

Which biological markers are claimed in FibroBiologics' cachexia patent No. 3118732?

Claims specify fibroblasts expressing markers like SSEA3, SSEA4, Tra-1-60, Tra-1-81, Oct-4, CD13, CD44, CD49b, CD105, and aminopeptidase N. According to the company, these marker profiles differentiate therapeutic fibroblasts from non-therapeutic cells.

What next steps should investors expect after FibroBiologics (FBLG) received the Canadian patent?

Investors should expect continued clinical development and potential expansion of IP filings in other regions. According to the company, the patent expands global IP protection and supports ongoing efforts to advance fibroblast therapies toward clinical and regulatory milestones.